Compare JetBlue Airways Corporation (JBLU) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Pfizer Inc — how do they compare? JetBlue Airways Corporation trades at $3.86 (market cap $1.48B), while Pfizer Inc trades at $27.86 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 107.1× JetBlue Airways Corporation's market cap, and Pfizer Inc pays a 6.18% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Pfizer Inc for 158 Days on average.
| JBLU | PFE | |
|---|---|---|
Market Cap | $1.48B | $158.56B |
Volume | 30,275,693 | 44,138,282 |
Sector | Industrials | Health |
52-Week High | $6.46 | $29.02 |
52-Week Low | $3.92 | $23.67 |
Typical Hold Time | 44 Days | 158 Days |
Enterprise Value | $8.84B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.97, down 1.49% today, with a bearish technical outlook despite oversold RSI levels. The airline faces fundamental challenges with consecutive quarterly losses, negative profit margins (-9.32%), and elevated debt levels (debt-to-asset ratio of 51.28% in 2025). Recent developments include route expansion to Colombia and the launch of premium BlueFirst seating, but operational cash flow remains negative (-$94M in 2025).
The investment outlook is cautious given persistent losses and high leverage, though the current valuation (P/S 0.15, P/B 0.93) appears discounted. Analyst consensus is mixed with a $5.89 price target (48% upside) but predominantly Hold ratings (62%). Key risks include fuel cost volatility, competitive pressure, and macroeconomic sensitivity to travel demand.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
